medigraphic.com
ISSN 2500-7106 (Electronic)
ISSN 0123-2576 (Print)
Medicina & Laboratorio

2021, Number 3

<< Back Next >>

Medicina & Laboratorio 2021; 25 (3)

Hemophilia A: a rare disease

Santiago-Pacheco V, Vizcaíno-Carruyo J

Language: Spanish
References: 57
Page: 605-617
PDF size: 170.22 Kb.


ABSTRACT

Hemophilia A is an X-linked inherited disease caused by mutations in the coagulation factor VIII F8 gene. It is considered a rare disease, as its prevalence is 26.6 per 100,000 live male births. Patients with hemophilia A have a relatively normal coagulation onset and amplification phases, and are able to form the initial platelet plug at the site of hemorrhage; but due to factor VIII deficiency, they are unable to generate a sufficient amount of thrombin on the platelet surface to stabilize the fibrin clot. In a male patient with unusual bleeding, a hemophilia A-type coagulation disorder should be ruled out, and blood tests such as a platelet count and prothrombin time (PT), which are usually normal, and an activated partial thromboplastin time (APTT), which is prolonged, should be requested immediately. For differential diagnosis with other coagulopathies, measurement of coagulation factors and correction tests are performed when there is suspicion of an inhibitor or acquired hemophilia. Affected patients may present mild, moderate or severe forms of the disease, depending on the plasma level of the factor. In Colombia and worldwide, hemophilia was recognized as a rare disease that represents a public health problem due to its highly specialized care, which increases the costs associated with health care, and affects the quality of life of patients and those around them, as well as representing a diagnostic challenge that requires constant updating, so that it can be treated effectively.


REFERENCES

  1. Acosta-Aragón MA, Álvarez-Mina AR,Velásquez-Paz JC, Vizcaíno-Carruyo JC.Hemofilia B o enfermedad de Christmas.Med Lab 2020;24:273-289. https://doi.org/10.36384/01232576.336.

  2. Alvis LF, Sánchez P, Acuña L, Escobar G, LinaresA, Solano MH, et al. National registry ofhaemophilia and other coagulopathies: A multisectorinitiative in the Colombian Health System.Haemophilia 2020;26:e254-261. https://doi.org/https://doi.org/10.1111/hae.14138.

  3. World Federation of Hemophilia (WFH). Reporton the Annual Global Survey 2019. Montréal, Canada:World Federation of Hemophilia; 2020. Acceso11 de mayo de 2021. Disponible en http://www1.wfh.org/publications/files/pdf-1806.pdf.

  4. Iorio A, Stonebraker JS, Chambost H, MakrisM, Coffin D, Herr C, et al. Establishing the prevalenceand prevalence at birth of hemophiliain males: A meta-analytic approach using nationalregistries. Ann Intern Med 2019;171:540-

  5. https://doi.org/10.7326/m19-1208.5. Srivastava A, Santagostino E, Dougall A, KitchenS, Sutherland M, Pipe SW, et al. WFHGuidelines for the Management of Hemophilia,3rd edition. Haemophilia 2020;26:1-158.https://doi.org/10.1111/hae.14046.

  6. Biggs R, Douglas AS, Macfarlane RG, DacieJV, Pitney WR, Merskey. Christmas disease:a condition previously mistaken for haemophilia.Br Med J 1952;2:1378-1382. https://doi.org/10.1136/bmj.2.4799.1378.

  7. Konkle BA, Huston H, Nakaya Fletcher S.Hemophilia A. GeneReviews®. Seattle (WA):University of Washington; 2017. Acceso 10de mayo de 2021. Disponible en https://www.ncbi.nlm.nih.gov/books/NBK1404/.

  8. Miller CH, Bean CJ. Genetic causes of haemophiliain women and girls. Haemophilia2021;27:e164-179. https://doi.org/10.1111/hae.14186.

  9. Kizilocak H, Young G. Diagnosis andtreatment of hemophilia. Clin Adv Hematol Oncol2019;17:344-351.

  10. Cervera-Bravo A. Fisiopatología y trastornosde la coagulación hereditarios más frecuentes.Pediatr Integral 2012;XVI:387-398.

  11. Ferreira CN, de Oliveira-Sousa M, Sant'Ana-Dusse LM, Carvalho Md. O novo modelo dacascata de coagulação baseado nas superfíciescelulares e suas implicações. Rev Bras HematolHemoter 2010;32:416-421.

  12. Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, SrivastavaA. Definitions in hemophilia: communicationfrom the SSC of the ISTH. J Thromb Haemost2014;12:1935-1939. https://doi.org/10.1111/jth.12672.

  13. Aghighi S, Riddell A, Lee CA, Brown SA,Tuddenham E, Chowdary P. Global coagulationassays in hemophilia A: A comparison toconventional assays. Res Pract Thromb Haemost2020;4:298-308. https://doi.org/10.1002/rth2.12295.

  14. van den Berg HM, De Groot PH, Fischer K.Phenotypic heterogeneity in severe hemophilia.J Thromb Haemost 2007;5:S151-156. https://doi.org/10.1111/j.1538-7836.2007.02503.x.

  15. Hoyer LW. Hemophilia A. N Engl J Med1994;330:38-47. https://doi.org/10.1056/nejm199401063300108.

  16. Acharya SS, Kaplan RN, Macdonald D, FabiyiOT, DiMichele D, Lyden D. Neoangiogenesiscontributes to the development of hemophilicsynovitis. Blood 2011;117:2484-2493. https://doi.org/10.1182/blood-2010-05-284653.

  17. Jansen NW, Roosendaal G, Lafeber FP.Understanding haemophilic arthropathy:an exploration of current open issues. Br JHaematol 2008;143:632-640. https://doi.org/10.1111/j.1365-2141.2008.07386.x.

  18. Witmer C, Presley R, Kulkarni R, Soucie JM,Manno CS, Raffini L. Associations betweenintracranial haemorrhage and prescribedprophylaxis in a large cohort of haemophiliapatients in the United States. Br J Haematol2011;152:211-216. https://doi.org/10.1111/j.1365-2141.2010.08469.x.

  19. McKusick VA, Hamosh A. Hemophilia A. Baltimore,USA: Online Mendelian Inheritancein Man (OMIM); 2018. Acceso 13 de mayo de

  20. 2021. Disponible en https://omim.org/entry/306700.20. Attard C, van der Straaten T, Karlaftis V, MonagleP, Ignjatovic V. Developmental hemostasis:age-specific differences in the levels of hemostaticproteins. J Thromb Haemost 2013;11:1850-1854. https://doi.org/10.1111/jth.12372.

  21. Sato K, Katori N, Suga Y, Kiyama S, UezonoS. Coagulation assessment with thromboelastographyduring abdominal endovascular aneurysmrepair in a patient with hemophilia A. JA ClinicalReports 2020;6:7. https://doi.org/10.1186/s40981-020-0316-0.

  22. Rodeghiero F, Tosetto A, Abshire T, ArnoldDM, Coller B, James P, et al. ISTH/SSC bleedingassessment tool: a standardized questionnaireand a proposal for a new bleeding score for inheritedbleeding disorders. J Thromb Haemost2010;8:2063-2065. https://doi.org/10.1111/j.1538-7836.2010.03975.x.

  23. Srivastava A. Diagnosis of haemophiliaand other inherited bleeding disorders -Is a new paradigm needed? Haemophilia2021;27:s14-20. https://doi.org/10.1111/hae.14042.

  24. Borhany M, Fatima N, Abid M, Shamsi T, OthmanM. Application of the ISTH bleeding score inhemophilia. Transfus Apher Sci 2018;57:556-560.https://doi.org/10.1016/j.transci.2018.06.003.

  25. Gouw SC, van den Berg HM, Oldenburg J,Astermark J, de Groot PG, Margaglione M,et al. F8 gene mutation type and inhibitor developmentin patients with severe hemophiliaA: systematic review and meta-analysis. Blood2012;119:2922-2934. https://doi.org/10.1182/blood-2011-09-379453.

  26. Bagnall RD, Waseem N, Green PM, GiannelliF. Recurrent inversion breaking intron 1 of thefactor VIII gene is a frequent cause of severehemophilia A. Blood 2002;99:168-174. https://doi.org/10.1182/blood.v99.1.168.

  27. Giancarlo C, Davide M. Hemophilia A and B: molecularand clinical similarities and differences.Haematologica 2019;104:1702-1709. https://doi.org/10.3324/haematol.2019.221093.

  28. Plug I, Mauser-Bunschoten EP, Bröcker-Vriends AH, van Amstel HK, van der BomJG, van Diemen-Homan JE, et al. Bleeding incarriers of hemophilia. Blood 2006;108:52-56.https://doi.org/10.1182/blood-2005-09-3879.

  29. Paroskie A, Gailani D, DeBaun MR, SidonioRF, Jr. A cross-sectional study of bleeding phenotypein haemophilia A carriers. Br J Haematol2015;170:223-228. https://doi.org/10.1111/bjh.13423.

  30. Mannucci PM. Back to the future: a recenthistory of haemophilia treatment. Haemophilia2008;14:S10-18. https://doi.org/10.1111/j.1365-2516.2008.01708.x.

  31. Franchini M, Mannucci PM. Past, presentand future of hemophilia: a narrative review.Orphanet J Rare Dis 2012;7:24. https://doi.org/10.1186/1750-1172-7-24.

  32. Mannucci PM, Tuddenham EG. The hemophilias--from royal genes to gene therapy. NEngl J Med 2001;344:1773-1779. https://doi.org/10.1056/nejm200106073442307.

  33. Kempton CL, Makris M, Holme PA. Managementof comorbidities in haemophilia. Haemophilia2021;27:s37-45. https://doi.org/10.1111/hae.14013.

  34. Pipe SW, Kaczmarek R, Srivastava A, PierceGF, Makris M, Hermans C. Management ofCOVID-19-associated coagulopathy in personswith haemophilia. Haemophilia 2021;27:41-48.https://doi.org/10.1111/hae.14191.

  35. Franchini M. The modern treatment of haemophilia:a narrative review. Blood Transfus 2013;11:178-182. https://doi.org/10.2450/2012.0166-11.

  36. Fuenmayor-Castaño A, Jaramillo-RestrepoM, Salinas-Durán F. Calidad de vida en una poblacióncon hemofilia: estudio de corte transversalen un centro de tratamiento de hemofilia.Rev Colomb Reumatol 2017;24:18-24. https://doi.org/10.1016/j.rcreu.2016.10.006.

  37. Shima M, Hanabusa H, Taki M, Matsushita T,Sato T, Fukutake K, et al. Factor VIII-mimeticfunction of humanized bispecific antibody in hemophiliaA. N Engl J Med 2016;374:2044-2053.https://doi.org/10.1056/NEJMoa1511769.

  38. Zhao Y, Weyand AC, Shavit JA. Noveltreatments for hemophilia through rebalancingof the coagulation cascade. Pediatr Blood Cancer2021;68:e28934. https://doi.org/10.1002/pbc.28934.

  39. Petersen LC. Hemostatic properties of a TFPIantibody. Thromb Res 2012;129:S44-45. https://doi.org/10.1016/j.thromres.2012.02.030.

  40. Shapiro AD, Angchaisuksiri P, AstermarkJ, Benson G, Castaman G, ChowdaryP, et al. Subcutaneous concizumab prophylaxisin hemophilia A and hemophilia A/Bwith inhibitors: phase 2 trial results. Blood2019;134:1973-1982. https://doi.org/10.1182/blood.2019001542.

  41. Croteau SE, Wang M, Wheeler AP. 2021 clinicaltrials update: Innovations in hemophilia therapy.Am J Hematol 2021;96:128-144. https://doi.org/10.1002/ajh.26018.

  42. Pierce GF. Uncertainty in an era of transformativetherapy for haemophilia: Addressing theunknowns. Haemophilia 2021;27:s103-113.https://doi.org/10.1111/hae.14023.

  43. Pipe SW. Gene therapy for hemophilia. PediatrBlood Cancer 2018;65. https://doi.org/10.1002/pbc.26865.

  44. Peyvandi F, Garagiola I, Young G. Thepast and future of haemophilia: diagnosis,treatments, and its complications. Lancet2016;388:187-197. https://doi.org/10.1016/s0140-6736(15)01123-x.

  45. Cannavò A, Valsecchi C, Garagiola I, Palla R,Mannucci PM, Rosendaal FR, et al. Nonneutralizingantibodies against factor VIII and riskof inhibitor development in severe hemophiliaA. Blood 2017;129:1245-1250. https://doi.org/10.1182/blood-2016-06-720086.

  46. Gringeri A, Mantovani LG, Scalone L, MannucciPM. Cost of care and quality of life forpatients with hemophilia complicated byinhibitors: the COCIS Study Group. Blood2003;102:2358-2363. https://doi.org/10.1182/blood-2003-03-0941.

  47. Mancuso ME, Mahlangu JN, Pipe SW. Thechanging treatment landscape in haemophilia:from standard half-life clotting factorconcentrates to gene editing. Lancet2021;397:630-640. https://doi.org/10.1016/s0140-6736(20)32722-7.

  48. Lim MY, Cheng D, Recht M, Kempton CL, KeyNS. Management of inhibitors in persons withnon-severe hemophilia A in the United States.Am J Hematol 2021;96:e9-11. https://doi.org/10.1002/ajh.26011.

  49. Gallo-Durán S, Castillo-Jiménez A, Villalobos-Alvarado G, Caro-Pizarro V, Arroyo-QuirósA. Hemofilia, una revisión de la literatura.Cron Cient 2020;14:6-21.

  50. Franchini M, Veneri D, Lippi G. Inheritedfactor XI deficiency: a concise review. Hematology2006;11:307-309. https://doi.org/10.1080/10245330600921964.

  51. Andreas T, Peter C, Paul K, Jerome T,Craig K, Midori S, et al. International recommendationson the diagnosis andtreatment of acquired hemophilia A. Haematologica2020;105:1791-1801. https://doi.org/10.3324/haematol.2019.230771.

  52. Franchini M, Schiavulli M, Liumbruno GM. Hemostatictherapy as a management strategy foracquired hemophilia: what does the future hold?Expert Rev Hematol 2021;14:263-270. https://doi.org/10.1080/17474086.2021.1892483.

  53. Liga Colombiana de Hemofílicos y Otras DeficienciasSanguíneas. ColHemofílicos. Bogotá,Colombia: Liga Colombiana de Hemofílicosy Otras Deficiencias Sanguíneas; 2021. Acceso13 de mayo de 2021. Disponible en http://colhemofilicos.org.co/.

  54. Acuña-Merchán L, Soler LA, Valderrama F,Daza MT, Fuentes JC. Situación de la hemofiliaen Colombia 2017. Cuenta de alto costo,Fondo Colombiano de Enfermedades de AltoCosto. Bogotá, Colombia: Fondo Colombianode Enfermedades de Alto Costo; 2018. Acceso12 de mayo de 2021. Disponible en http://colhemofilicos.org.co/index.php/eventoscolhemofilicos/situacion-de-la-hemofilia-encolombia-2017.

  55. Sánchez-Duque JA. Características clínicasy epidemiológicas de pacientes con hemofiliadel eje cafetero, Colombia. Rev Cient CienMed 2017;20:15-20. https://doi.org/10.51581/rccm.v20i2.117.

  56. Mijares ME, Boadas de Sánchez A. Tratamientoprofiláctico en la hemofilia en países de laregión Latinoamericana. Un reporte del GrupoLatinoamericano para el Impulso del Tratamientode la Hemofilia (GLAITH). Invest Clin2015;56:264-275.

  57. Martínez-Sánchez LM, Álvarez-HernándezLF, Ruiz-Mejía C, Jaramillo-Jaramillo LI,Builes-Restrepo LN, Villegas-Álzate JD. Hemofilia:abordaje diagnóstico y terapéutico. Revisiónbibliográfica. Rev Fac Nac Salud Pública2018;36:85-93.




2020     |     www.medigraphic.com